New Frontiers in Treatment for Retroperitoneal Sarcoma
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 284
Special Issue Editors
2. Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
3. Department of Surgery, University of Toronto,Toronto, ON, Canada
Interests: retroperitoneal sarcoma; surgery; resection; gastrointestinal stromal tumour; gastric adenocarcinoma; recurrent rectal cancer; prognosis; recurrence patterns
Interests: retroperitoneal sarcoma; gastrointestinal malignancy; breast cancer; cancer biology; metastasis; precision oncology; surgical oncology; translational research
Special Issue Information
Dear Colleagues,
Retroperitoneal sarcomas (RPSs) are a rare and heterogeneous group of neoplasms. Over the last decade, international collaborative efforts have led to significant advancements in the understanding of RPS biology, ultimately aiming to improve patient outcomes through the standardization of management. Landmark works stemming from these efforts have demonstrated the importance of tumor histological subtype in dictating the clinical behavior of RPS. While surgical excision with the en bloc resection of involved contiguous organs remains the only curative treatment, there is emerging data supporting histology-specific multimodal therapy. Through this collaborative framework, prospective randomized clinical trials are generating evidence-based treatment strategies. As this data matures, its integration into clinical decision-making requires multidisciplinary expertise at specialized sarcoma units. This is particularly relevant in the setting of recurrent or metastatic disease, where translational studies are needed to identify novel targetable molecular vulnerabilities.
This Special Issue invites original research studies and reviews exploring the new frontiers in the treatment of RPS. In particular, we welcome articles focusing on emerging histology-specific surgical, radiation, and systemic therapeutic strategies targeting primary, recurrent, and metastatic disease.
Dr. Carol J. Swallow
Dr. Paul Savage
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- retroperitoneal sarcoma
- surgery
- chemotherapy
- radiation therapy
- neoadjuvant therapy
- histology-specific therapy
- targeted therapy
- immunotherapy
- biomarkers
- recurrence
- metastasis
